Sana Biotechnology (NASDAQ:SANA) Shares Up 10.4% - Still a Buy?

Key Points

• Sana Biotechnology shares rose 10.4% to $3.225, although trading volume was 83% below the stock’s average daily volume.
• Analyst views remain mixed, but the overall consensus is “Moderate Buy”, with an average price target of $9.33 versus the current price.
• Sana reported a quarterly loss of $0.13 per share, beating estimates for a $0.15 loss; analysts still expect a full-year loss of approximately $0.72 per share, while institutional investors own 88.23% of the stock.

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report)'s stock price rose 10.4% on Thursday . The company traded as high as $3.24 and last traded at $3.2250. 533,247 shares traded hands during trading, a decline of 83% from the average daily volume of 3,137,957 shares. The stock had previously closed at $2.92.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on SANA shares. Wall Street Zen cut Sana Biotechnology from a "hold" rating to a "sell" rating in a report on Monday, July 20th. TD Cowen raised Sana Biotechnology to a "strong-buy" rating in a research note on Monday, August 24th. Bank of America decreased their target price on Sana Biotechnology from $7.00 to $6.00 and set a "buy" rating on the stock in a report on Friday, August 14th. Finally, Weiss Ratings raised Sana Biotechnology from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $9.33.

Sana Biotechnology Stock Up 8.4%

The firm's 50-day moving average price is $3.53 and its two-hundred day moving average price is $3.37. The firm has a market capitalization of $947.47 million, a PE ratio of -4.16 and a beta of 2.12.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.02. Equities research analysts forecast that Sana Biotechnology, Inc. will post -0.72 EPS for the current year.

Institutional Trading of Sana Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of the business. Rockefeller Capital Management L.P. increased its position in Sana Biotechnology by 74.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company's stock worth $39,000 after buying an additional 4,088 shares during the period. Royal Bank of Canada boosted its position in shares of Sana Biotechnology by 76.8% in the first quarter. Royal Bank of Canada now owns 12,285 shares of the company's stock valued at $35,000 after acquiring an additional 5,338 shares during the period. Swiss National Bank boosted its position in shares of Sana Biotechnology by 2.0% in the first quarter. Swiss National Bank now owns 342,600 shares of the company's stock valued at $987,000 after acquiring an additional 6,800 shares during the period. Cetera Investment Advisers grew its stake in shares of Sana Biotechnology by 50.2% in the first quarter. Cetera Investment Advisers now owns 26,181 shares of the company's stock worth $75,000 after acquiring an additional 8,750 shares during the last quarter. Finally, Walleye Capital LLC acquired a new stake in shares of Sana Biotechnology in the second quarter worth $35,000. Institutional investors and hedge funds own 88.23% of the company's stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc is a clinical-stage biotechnology company focused on developing engineered cells and gene therapies for the treatment of serious diseases. The company's approach is designed to create therapeutic cells that can be delivered to patients without requiring individualized manufacturing, potentially broadening access to cell-based medicines.

Sana is developing technologies intended to address key challenges in cell and gene therapy, including immune rejection, targeted delivery of genetic material and the production of engineered cells at scale.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.